Navigation Links
Elsevier's Maturitas publishes clinical guide on endometrial assessment in postmenopausal women

Amsterdam, May 8, 2013 Elsevier, a world-leading provider of scientific, technical and medical information products and services, announced today the publication of a clinical guide by the European Menopause and Andropause Society (EMAS) in the journal Maturitas on endometrial assessment in peri and postmenopausal women with summary recommendations.

The main onus of endometrial assessment is to exclude carcinoma of the endometrium and premalignant endometrial hyperplasia. Assessment of the endometrium in the absence of bleeding should be limited to women at high risk of endometrial cancer. Transvaginal ultrasound scanning (TVS) is used for initial assessment to be followed by endometrial biopsy to be undertaken as an outpatient procedure if possible. Hysteroscopy allows direct visualization of the endometrial cavity and any focal lesions. Should results be inconclusive and abnormal or postmenopausal bleeding persist, transvaginal ultrasound should be repeated and hysteroscopy performed.

These and other recommendations presented in EMAS' clinical guide are published in the article: 'EMAS clinical guide: Assessment of the endometrium in peri and postmenopausal women', by Eva Dreisler, Lars Grnlund Poulsen, Sofie Leisby Antonsen, Iuliana Ceausu, Herman Depypere, C. Tamer Erel, Irene Lambrinoudaki, Faustino R. Prez-Lpez, Tommaso Simoncini, Florence Tremollieres, Margaret Rees and Lian Ulrich (10.1016/j.maturitas.2013.03.011).The article appears in Maturitas Volume 75, Issue 2 (June 2013), published by Elsevier.


Contact: Greyling Peoples

Page: 1

Related biology news :

1. Leading RSV researcher publishes work at Le Bonheur Childrens
2. PeerJ publishes its first articles
3. Mercury releases contaminate ocean fish: Dartmouth-led effort publishes major findings
4. Professor publishes on first-ever imaging of cells growing on spherical surfaces
5. NYBG press publishes final volume of landmark Intermountain Flora series
6. The ENCODE Project publishes new genomic insights in special issue of Genome Research
7. Canadian Journal of Cardiology publishes new atrial fibrillation guidelines
8. Clinical Tests Demonstrate Long-Term Effectiveness of Oral Glutathione Supplements - Kyowa Study
9. Genetic and clinical factors best to predict late recurrence in estrogen receptor POS breast cancer
10. Federal Government Organization achieves cleaner and faster Clinical Study Data using Tablet PCs from TabletKiosk
11. AACR news: Paragazole excels in preclinical models of triple-negative breast cancer
Post Your Comments:
(Date:11/16/2015)... Calif. , Nov 16, 2015  Synaptics ... of human interface solutions, today announced expansion of ... TouchView ™ touch controller and display driver ... revolution of smartphones. These new TDDI products add ... TD4100 (HD resolution), TD4302 (WQHD resolution), and TD4322 ...
(Date:11/10/2015)... , Nov. 10, 2015  In this ... the basis of product, type, application, disease ... in this report are consumables, services, software. ... are safety biomarkers, efficacy biomarkers, and validation ... report are diagnostics development, drug discovery and ...
(Date:11/2/2015)... Nov. 2, 2015  SRI International has been awarded ... preclinical development services to the National Cancer Institute (NCI) ... provide scientific expertise, modern testing and support facilities, and ... pharmacology and toxicology studies to evaluate potential cancer prevention ... The PREVENT Cancer Drug Development Program is an NCI-supported ...
Breaking Biology News(10 mins):
(Date:11/26/2015)... CHESHAM , England , November 26, ... Lightpoint Medical, an innovative medical device company specializing in ... Euro grant from the European Commission as part of the ... enabling the company to carry out a large-scale clinical trial ... -->      (Logo: , ...
(Date:11/25/2015)... Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) ... a stockholder rights plan (Rights Plan) in an effort ... carryforwards (NOLs) under Section 382 of the Internal Revenue ... PharmAthene,s use of its NOLs could be substantially ... defined in Section 382 of the Code. In general, ...
(Date:11/25/2015)... -- Studies reveal the differences in species ... the way for more effective treatment for one of the ... --> --> Gum disease ... cats, yet relatively little was understood about the bacteria associated ... conducted by researchers from the WALTHAM Centre for Pet Nutrition ...
(Date:11/25/2015)... 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) ... CEO of Neurocrine Biosciences, will be presenting at the ... New York . .   ... 5 minutes prior to the presentation to download or ... will be available on the website approximately one hour ...
Breaking Biology Technology: